EXACT SCIENCES CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that EXACT SCIENCES CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2013 | $1.04M | Feb 27, 2015 |
| FY2014 | Sep 30, 2013 | $1.04M | Feb 27, 2015 |
| FY2014 | Jun 30, 2013 | $1.04M | Feb 27, 2015 |
| FY2014 | Mar 31, 2013 | $1.04M | Feb 27, 2015 |
| FY2013 | Dec 31, 2012 | $1.04M | Feb 28, 2014 |
| FY2013 | Sep 30, 2012 | $1.04M | Feb 28, 2014 |
| FY2013 | Jun 30, 2012 | $1.04M | Feb 28, 2014 |
| FY2013 | Mar 31, 2012 | $1.04M | Feb 28, 2014 |
| FY2012 | Dec 31, 2011 | $1.04M | Mar 1, 2013 |
| FY2012 | Sep 30, 2011 | $1.04M | Mar 1, 2013 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.25B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.76B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $2.50B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $2.08B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $1.77B | Feb 21, 2024 |
| FY2021 | Dec 31, 2020 | $1.49B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $876.29M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $454.46M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $265.99M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $99.38M | Feb 21, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $99.38M | Feb 21, 2017 |
| FY2016 | Dec 31, 2015 | $39.44M | Feb 21, 2017 |
| FY2016 | Dec 31, 2014 | $1.80M | Feb 21, 2017 |
| FY2015 | Dec 31, 2013 | $4.14M | Feb 24, 2016 |
| FY2014 | Dec 31, 2012 | $4.14M | Feb 27, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.26B | Feb 13, 2026 |
| FY2024 | Dec 31, 2024 | $492.59M | Feb 19, 2025 |
| FY2024 | Sep 30, 2024 | $491.49M | Feb 19, 2025 |
| FY2024 | Jun 30, 2024 | $488.32M | Feb 19, 2025 |
| FY2024 | Mar 31, 2024 | $446.32M | Feb 19, 2025 |
| FY2024 | Dec 31, 2023 | $453.92M | Feb 19, 2025 |
| FY2024 | Sep 30, 2023 | $439.03M | Feb 19, 2025 |
| FY2024 | Jun 30, 2023 | $444.38M | Feb 19, 2025 |
| FY2024 | Mar 31, 2023 | $424.87M | Feb 19, 2025 |
| FY2024 | Dec 31, 2022 | $1.42B | Feb 19, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($207.95M) | Feb 13, 2026 |
| FY2024 | Dec 31, 2024 | ($864.59M) | Feb 19, 2025 |
| FY2024 | Sep 30, 2024 | ($38.24M) | Feb 19, 2025 |
| FY2024 | Jun 30, 2024 | ($15.81M) | Feb 19, 2025 |
| FY2024 | Mar 31, 2024 | ($110.23M) | Feb 19, 2025 |
| FY2024 | Dec 31, 2023 | ($49.77M) | Feb 19, 2025 |
| FY2024 | Sep 30, 2023 | $794.0K | Feb 19, 2025 |
| FY2024 | Jun 30, 2023 | ($81.03M) | Feb 19, 2025 |
| FY2024 | Mar 31, 2023 | ($74.15M) | Feb 19, 2025 |
| FY2024 | Dec 31, 2022 | ($623.51M) | Feb 19, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($206.30M) | Feb 13, 2026 |
| FY2024 | Dec 31, 2024 | ($876.35M) | Feb 19, 2025 |
| FY2024 | Sep 30, 2024 | ($39.40M) | Feb 19, 2025 |
| FY2024 | Jun 30, 2024 | ($26.26M) | Feb 19, 2025 |
| FY2024 | Mar 31, 2024 | ($106.69M) | Feb 19, 2025 |
| FY2024 | Dec 31, 2023 | ($67.84M) | Feb 19, 2025 |
| FY2024 | Sep 30, 2023 | $6.85M | Feb 19, 2025 |
| FY2024 | Jun 30, 2023 | ($76.93M) | Feb 19, 2025 |
| FY2024 | Mar 31, 2023 | ($77.09M) | Feb 19, 2025 |
| FY2024 | Dec 31, 2022 | ($593.51M) | Feb 19, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $523.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2024 | $97.71M | Feb 19, 2025 |
| FY2024 | Sep 30, 2024 | $101.49M | Feb 19, 2025 |
| FY2024 | Jun 30, 2024 | $121.15M | Feb 19, 2025 |
| FY2024 | Mar 31, 2024 | $110.87M | Feb 19, 2025 |
| FY2024 | Dec 31, 2023 | $115.18M | Feb 19, 2025 |
| FY2024 | Sep 30, 2023 | $111.71M | Feb 19, 2025 |
| FY2024 | Jun 30, 2023 | $104.36M | Feb 19, 2025 |
| FY2024 | Mar 31, 2023 | $95.68M | Feb 19, 2025 |
| FY2024 | Dec 31, 2022 | $394.19M | Feb 19, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $491.44M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $210.54M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $156.12M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | ($223.56M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | ($102.24M) | Feb 21, 2024 |
| FY2021 | Dec 31, 2020 | $136.48M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | ($111.66M) | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | ($68.94M) | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | ($71.72M) | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | ($130.07M) | Feb 21, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $134.66M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $135.99M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $124.19M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $214.46M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $135.77M | Feb 21, 2024 |
| FY2021 | Dec 31, 2020 | $65.08M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $172.65M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $150.09M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $48.48M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $14.85M | Feb 21, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.86B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $5.93B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $6.47B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $6.23B | Feb 21, 2024 |
| FY2021 | Dec 31, 2021 | $6.68B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $4.93B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $3.51B | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $1.52B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $598.56M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $377.04M | Feb 22, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.46B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $3.53B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $3.33B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $3.18B | Feb 21, 2024 |
| FY2021 | Dec 31, 2021 | $3.30B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $2.69B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $1.22B | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $843.08M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $78.14M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $41.75M | Feb 22, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.40B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.40B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $3.15B | Feb 13, 2026 |
| FY2025 | Dec 31, 2022 | $3.04B | Feb 13, 2026 |
| FY2024 | Dec 31, 2021 | $3.39B | Feb 19, 2025 |
| FY2023 | Dec 31, 2020 | $2.24B | Feb 21, 2024 |
| FY2021 | Dec 31, 2019 | $1.96B | Feb 21, 2023 |
| FY2021 | Dec 31, 2018 | $447.26M | Feb 22, 2022 |
| FY2020 | Dec 31, 2017 | $520.42M | Feb 16, 2021 |
| FY2019 | Dec 31, 2016 | $335.30M | Feb 21, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.37B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.37B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $2.37B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $2.35B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $2.34B | Feb 21, 2024 |
| FY2021 | Dec 31, 2020 | $1.24B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $1.20B | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $17.28M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $1.98M | Feb 21, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.71B) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | ($4.50B) | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | ($3.47B) | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | ($3.27B) | Feb 21, 2024 |
| FY2021 | Dec 31, 2021 | ($2.64B) | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | ($2.05B) | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | ($1.12B) | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | ($1.04B) | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | ($860.61M) | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | ($745.82M) | Feb 22, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $956.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $600.89M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $605.38M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $242.49M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $315.47M | Feb 21, 2024 |
| FY2021 | Dec 31, 2020 | $1.49B | Feb 21, 2023 |
| FY2020 | Dec 31, 2019 | $177.25M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $160.43M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $77.49M | Feb 21, 2019 |
| FY2018 | Dec 31, 2016 | $48.92M | Feb 21, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $23.75M | Feb 16, 2021 |
| FY2019 | Dec 31, 2019 | $25.00M | Feb 21, 2020 |
| FY2018 | Dec 31, 2018 | $24.26M | Feb 21, 2019 |
| FY2017 | Dec 31, 2017 | $4.68M | Feb 22, 2018 |
| FY2016 | Dec 31, 2016 | $4.85M | Feb 21, 2017 |
| FY2015 | Dec 31, 2015 | $5.02M | Feb 24, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 13, 2026 |
| FY2024 | Dec 31, 2024 | (4) | Feb 19, 2025 |
| FY2024 | Sep 30, 2024 | 0 | Feb 19, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Feb 19, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Feb 19, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Feb 19, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Feb 19, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Feb 19, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Feb 19, 2025 |
| FY2024 | Dec 31, 2022 | (3) | Feb 19, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 13, 2026 |
| FY2024 | Dec 31, 2024 | (4) | Feb 19, 2025 |
| FY2024 | Sep 30, 2024 | 0 | Feb 19, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Feb 19, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Feb 19, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Feb 19, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Feb 19, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Feb 19, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Feb 19, 2025 |
| FY2024 | Dec 31, 2022 | (3) | Feb 19, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 190.80M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 185.62M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | 181.36M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 177.93M | Feb 21, 2024 |
| FY2021 | Dec 31, 2021 | 173.67M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | 159.42M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | 147.63M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | 123.19M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | 120.50M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | 110.24M | Feb 22, 2018 |